亚洲无线乱码高清在线观看一区,色一级,精品伊人久久,2018国产大陆天天弄,狠狠操夜夜爱,欧美日韩中文字幕在线,日本人视频网站一

首頁 /藥靶模型 /藥靶細(xì)胞 /激酶靶點(diǎn) /BCR-ABL1 [T315I]/BaF3

BCR-ABL1 [T315I]/BaF3

CBP73190

詢 價
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
I. Introduction
Cell Line Name: BCR-ABL1 [T315I]/BaF3
Host Cell: Ba/F3
Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application: Anti-proliferation assay and PD assay
Freeze Medium: 90% FBS+10% DMSO
Complete Culture Medium: RPMI-1640+10%FBS
Mycoplasma Status: Negative
 
II. Background

Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes.
ABL1 is a tyrosine kinase, and, in normal cells, it plays a role in cellular differentiation and regulation of the cell cycle. The BCR-ABL1 fusion gene creates a constitutively active tyrosine kinase, which leads to uncontrolled proliferation.
Imatinib is the first-generation ABL tyrosine kinase inhibitor, and it was approved by the FDA in 2001; label indications for CML include use in newly diagnosed adult and pediatric patients and in patients after failure of interferon-alpha therapy. While treatment responses to imatinib are often dramatic and lasting, 30–40% of patients will eventually need further treatment (Santos et al. 2011). In many but not all cases, this is due to the acquisition of point mutations in the tyrosine kinase domain of the BCR-ABL1 fusion gene, which renders the protein insensitive to the inhibitory effect of imatinib. This type of disease progression led to the development of second-line TKIs: dasatinib, nilotinib, and bosutinib. Dasatinib and bosutinib have the additional advantage of being inhibitors of SRC.
The second-generation TKIs, dasatinib, nilotinib, and bosutinib, are more potent than imatinib, and they were developed to treat cases of CML resistant to imatinib. Dasatinib and nilotinib are approved for use in CML in newly diagnosed adults, while dasatinib, nilotinib, and bosutinib are approved for use in adults with resistance or intolerance to prior therapy that included imatinib (FDA 2012). Soverini et al. (2011) made mutation-specific treatment decision recommendations that were adopted by NCCN (2012?). Recommendations based on preclinical data are as follows: for T315I, HSCT or clinical trial; for V299L, T315A, and F317L/V/I/C, consider nilotinib rather than dasatinib; for Y253H, E255K/V, and F359V/C/I, consider dasatinib rather than nilotinib; and for all other mutations, consider high-dose imatinib, dasatinib, or nilotinib.
Ponatinib is a third-line TKI, developed specifically to address imatinib resistance due to the BCR-ABL1 T315I resistance mutation. Ponatinib is currently being investigated in phase III clinical trials.

 
III. Representative Data

1. WB of BCR-ABL1 [T315I]/BaF3

2. Sanger of BCR-ABL1 [T315I]/BaF3

Figure 2. BCR-ABL1 T315I/BaF3 T315I

Figure 3. BCR-ABL1 T315I/BaF3 Fusion

 

3. Anti-proliferation assay

Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 T315I Cells.


藥靶模型聯(lián)系方式: 華東銷售經(jīng)理:18240630236 全國銷售經(jīng)理:18066071954
診斷標(biāo)準(zhǔn)品聯(lián)系方式: 華東銷售經(jīng)理:15000320447 華北銷售經(jīng)理:18131625521 華南銷售經(jīng)理:13484295986 華中&西南銷售經(jīng)理:13871580511 全國銷售經(jīng)理:13484295986

掃二維碼

立即提交
绥滨县| 黔南| 花垣县| 五指山市| 沂水县| 新郑市| 渝中区| 安新县| 淮滨县| 九台市| 茂名市| 廉江市| 尚志市| 阿拉善右旗| 循化| 安远县| 桦川县| 石景山区| 辽源市| 安仁县| 娄底市| 乾安县| 信丰县| 乐亭县| 明溪县| 宁城县| 虎林市| 遂平县| 饶阳县| 潞城市| 鄂托克旗| 长白| 栾城县| 章丘市| 苍山县| 七台河市| 永宁县| 肇源县| 洪泽县| 海城市| 博乐市|